Back to Search
Start Over
Two Patients with All-trans Retinoic Acid-Resistant Acute Promyelocytic Leukemia Treated Successfully with Gemtuzumab Ozogamicin as a Single Agent
- Source :
- International Journal of Hematology. 82:445-448
- Publication Year :
- 2005
- Publisher :
- Springer Science and Business Media LLC, 2005.
-
Abstract
- Acute promyelocytic leukemia (APL) cells express a considerable level of CD33, which is the target of gemtuzumab ozogamicin (GO), and a significantly lower level of P-glycoprotein (P-gp). Therefore, GO is predicted to be a successful treatment for APL. In this article, we report on the GO treatment of 2 patients with APL, who had fully relapsed after induction therapy with all -trans retinoic acid (ATRA) following chemotherapy. Both patients had relapsed 3 times and were resistant to reinduction therapy with ATRA. GO (9 mg/m2) was administered on days 1 and 15. After GO treatment, both patients achieved complete hematologic and molecular remission. GO may be another promising agent for the treatment of ATRA-resistant relapsed APL when given as salvage chemotherapy.
- Subjects :
- Male
Acute promyelocytic leukemia
medicine.medical_specialty
Gemtuzumab ozogamicin
medicine.medical_treatment
CD33
Retinoic acid
Antineoplastic Agents
Tretinoin
Pharmacology
Antibodies, Monoclonal, Humanized
chemistry.chemical_compound
Leukemia, Promyelocytic, Acute
Recurrence
immune system diseases
Internal medicine
medicine
Humans
ATP Binding Cassette Transporter, Subfamily B, Member 1
neoplasms
Chemotherapy
Hematology
business.industry
Remission Induction
Antibodies, Monoclonal
Middle Aged
medicine.disease
Gemtuzumab
Leukemia
Aminoglycosides
chemistry
Drug Resistance, Neoplasm
Cancer research
business
medicine.drug
Subjects
Details
- ISSN :
- 09255710
- Volume :
- 82
- Database :
- OpenAIRE
- Journal :
- International Journal of Hematology
- Accession number :
- edsair.doi.dedup.....ccd323f07c9b567ef7fe3d60ccd22a4b